Kaleido Biosciences jumps on positive data from liver disease trial

Kaleido Biosciences

12/12/2019 18:57

** Drug developer's shares  KLDO.O  up 17.3% at $6.04     
    ** Co reports positive data from an early study testing its
experimental liver disease treatment, KB174
    ** Treatment with KB174 was associated with a 26% reduction
in a measure of microbiome ammonia production; co's goal had
been 15% to 20%  urn:newsml:reuters.com:*:nGNXYpKK5
    ** Co says treatment was well-tolerated and there were no
serious treatment-related side effects observed
    ** KLDO to test KB174 to treat hepatic encephalopathy, a
decline in brain function that occurs as a result of severe
liver disease; expects to begin study during second half of 2020
    ** KB174 is a microbiome metabolic therapy designed to drive
the function and distribution of existing microbes in the gut to
treat disease 
    ** Up to Wednesday's close, stock had fallen ~64% YTD

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208;))